TGFB1 and neoplasm: Hybrid CARs with an extracellular TGF-β receptor domain linked to an intracellular NKG2D domain enhance anti-tumor activity in NK-92 cells and knocking down SMAD3, the downstream mediator of TGF-β, in NK cells improves cytotoxicity in solid tumors [75, 159].